Highlights• Ferric citrate effectively reduced blood phosphorus levels while increasing iron stores and decreasing the need for intravenous iron and anemia medications in dialysis patients.• The medication may help reduce complications and costs associated with kidney disease care.
More than 400,000 patients in the United States are on dialysis.
Newswise — Washington, DC (July 24, 2014) — A medication called ferric citrate may reduce dialysis patients’ need to take multiple drugs that treat complications related to kidney disease. Clinical trial results appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN) indicate that the medication is safe and effective and may even help cut costs.
More than 400,000 patients in the United States are on dialysis to treat their kidney disease. Most of these patients need to take medications that bind to phosphorus in their food to reduce toxic buildup of the mineral in their bodies. They also must take drugs to treat anemia, which commonly arises in patients with kidney disease because healthy kidneys are needed to generate the hormone that stimulates red blood cell production. Patients also tend to be iron deficient.
Dialysis patients usually have to take 3 different medications to overcome these 3 complications related to kidney disease: drugs that bind phosphorus, erythropoietin-stimulating agents (ESA) that boost blood cell production, and intravenous (IV) iron. Julia Lewis, MD (Vanderbilt University School of Medicine) and her colleagues in the Collaborative Study Group conducted a 441-patient randomized clinical trial to test the potential of a compound called ferric citrate to bind phosphorus, increase iron stores, and reduce the usage of IV iron and ESAs.
Patients were randomized to receive either ferric citrate or another phosphorus-binding agent for 52 weeks. This was then followed by a 4-week period in which patients taking ferric citrate were again randomized to either continue on the medication or switch to placebo.
The study investigators found that ferric citrate effectively reduced blood phosphorus levels while increasing iron stores and decreasing the need for IV iron and ESAs. “Ferric citrate binds the phosphorus in food and also increases iron in the blood, and it allows patients to need less or no IV iron and medicines to make their bone marrow produce more blood cells,” said Dr. Lewis. She also noted that patients on dialysis often experience many serious adverse medical events, many of which require hospitalization, and that ferric citrate was linked with fewer of these events compared with currently available phosphorus-binding medications. “While benefiting patients, ferric citrate is estimated to also actually reduce the cost of caring for dialysis patients by reducing IV iron and ESA usage, as well as hospitalizations.”
Study co-authors include Mohammed Sika, PhD, Mark Koury, MD, Peale Chuang, MD, FASN, Gerald Schulman, MD, Mark Smith, MD, Frederick Whittier, MD, Douglas Linfert, MD, Claude Galphin, MD, Balaji Athreya, MD, FASN, FASH, A. Kaldun Nossuli, MD, Ingrid Chang, MD, Samuel Blumenthal, MD, John Manley, MD, Steven Zeig, MD, Katagal Kant, MD, Tom Greene, PhD, and Jamie Dwyer, MD.
Disclosures: The Phosphate Binding and Iron Delivery with Ferric Citrate in ESRD (PERFECTED- CSG-15) Trial was funded by Keryx Biopharmaceuticals, Inc. This trial was also supported in part by a grant from The Patient Protection and Affordable Care Act of 2010. The Internal Revenue Service issued the funding under the Qualifying Therapeutic Discovery Project administered under section 48D of the Internal Revenue Code. All the authors declare that they have received research grants from or acted as a consultant to Keryx (NASDAQ: KERX), and received travel support from Keryx.
The article, entitled “Ferric Citrate Controls Phosphorus and Delivers Iron in Patients on Dialysis,” will appear online at http://jasn.asnjournals.org/ on July 24, 2014.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with more than 14,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.
MEDIA CONTACTRegister for reporter access to contact details
Journal of the American Society of Nephrology